| Issue Date | Title | Author(s) |
| Aug-2022 | Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthere (R)) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial | Shi, Yuankai; Zhang, Qingyuan; Hong, Xiaonan; Wang, Zhen; Gao, Yuhuan; Zou, Liqun; Cen, Hong; Gui, Lin; Li, Yufu; Feng, Jifeng; Wang, Zhao; Zhang, Mingzhi; Jin, Chuan; Zhang, Weihua; Hu, Jianda; Zheng, Chengyun; Zheng, Zhendong; Zhang, Liling; Chen, Shaoshui; Huang, Yunhong; Tang, Yun; Gao, Yajie; Hao, Miaowang; Li, Xiaoling; Chang, Chunkang; Yang, Haiyan; Wu, Hui; Shen, Lida; Ke, Xiaoyan; Zhang, Liangming; Xi, Yaming; Yang, Linhua; Xie, Liangzhi; Gai, Wenlin; Ji, Yanan |
| 2-Nov-2023 | Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8) | Song, Yuqin; Malpica, Luis; Cai, Qingqing; Zhao, Weili; Zhou, Keshu; Wu, Jianqiu; Zhang, Huilai; Ding, Kaiyang; Liu, Yao; Li, Zengjun; Mehta-Shah, Neha; Zhang, Liling; Zheng, Meifang; Jin, Jie; Yang, Haiyan; Shuang, Yuerong; Yoon, Dok Hyun; Gao, Sujun; Li, Wenyu; Zhai, Zhimin; Zou, Liqun; Xi, Yaming; Koh, Youngil; Li, Fei; Prince, Miles; Zhou, Hui; Lin, Lie; Liu, Hui; Yang, Zhenfan; Kim, Won Seog; Zhu, Jun |
| Jan-2024 | Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOTS Part B): a single-arm, multinational, phase 2 study | Song, Yuqin; Malpica, Luis; Cai, Qingqing; Zhao, Weili; Zhou, Keshu; Wu, Jianqiu; Zhang, Huilai; Mehta-Shah, Neha; Ding, Kaiyang; Liu, Yao; Li, Zengjun; Zhang, Liling; Zheng, Meifang; Jin, Jie; Yang, Haiyan; Shuang, Yuerong; Yoon, Dok Hyun; Gao, Sujun; Li, Wenyu; Zhai, Zhimin; Zou, Liqun; Xi, Yaming; Koh, Youngil; Li, Fei; Prince, Miles; Zhou, Hui; Lin, Lie; Liu, Hui; Allen, Pamela; Roncolato, Fernando; Yang, Zhenfan; Kim, Won-Seog; Zhu, Jun |
| 2-Nov-2023 | Loncastuximab Tesirine Demonstrated Substantial Single-Agent Efficacy and Manageable Safety Profile in Heavily Pretreated Chinese Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) | Lin, Ningjing; Sun, Xiuhua; Zhou, Hui; Zou, Liqun; Zhou, Keshu; Liu, Lihong; Yang, Haiyan; Hu, Kai; Cai, Qingqing; Liu, Yao; Jin, Jie; Zhang, Liling; Li, Wenyu; Guo, Ye; Yang, Wei; Luo, Feng; Li, Yanyan; Zhang, Mengqi; Lu, Feinan; Song, Yuqin; Zhu, Jun |
| 2-Nov-2023 | A Multicenter Phase2 Trial of Linperlisib in Relapsed or Refractory Peripheral T/NK Cell Lymphomas | Song, Yuqin; Li, Zengjun; Wu, Huijing; Jin, Jie; Zhou, Hui; Zhou, Keshu; Zhang, Liling; Peng, Zhigang; Zhang, Zhiye; Cen, Hong; Jia, Youchao; Shuang, Yuerong; Li, Zhiming; Yang, Haiyan; Zou, Liqun; Li, Zhifeng; Zhang, Zhihui; Li, Junmin; Cao, Junning; Qiu, Lugui; Wu, Shaojie; Gong, Tiejun; Xu, Xiaohong; Wang, Zhen; Zhu, Jun |
| 2-Nov-2023 | Phase 2 Search Study:XPO1 Inhibitor (ATG-010) Monotherapy in Heavily Pretreated Chinese Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Song, Yuqin; Cai, Qingqing; Zhang, Qingyuan; Sun, Xiuhua; Yang, Haiyan; Yao, Zhihua; Zou, Liqun; Zhang, Liling; Cao, Junning; Wang, Tingyu; Li, Lanfang; Liu, Yao; Jing, Hongmei; Gao, Sujun; Ding, Kaiyang; Liu, Bingshan; Zhao, Jun; Zhu, Jun |
| Jul-2024 | Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors | Song, Yuqin; Cao, Junning; Zhang, Qingyuan; Li, Caixia; Qiu, Lugui; Qi, Junyuan; Zhang, Huilai; Li, Wenyu; Liu, Lihong; Jing, Hongmei; Zhou, Keshu; Zhang, Weijing; Zhang, Liling; Li, Daqi; Zou, Liqun; Yang, Haiyan; Qian, Wenbin; Zhou, Hui; Hu, Jianda; Yin, Hongyan; Fu, Sisi; Fan, Songhua; Xu, Qian; Wang, Jian; Jia, Xiaoyun; Dai, Guangxiu; Su, Weiguo; Zhu, Jun |
| 26-Sep-2024 | Time to lymphoma treatment within 24 months in 'watch and wait' follicular lymphoma is associated with inferior outcomes: A multicentre analysis | Liu, Jing; Gao, Fenghua; Zhang, Tingting; Wang, Jiesong; Li, Zhiming; Liu, Lihong; Zhou, Hui; Zhang, Xudong; Sun, Xiuhua; Zhang, Wei; Xu, Bing; Su, Liping; Wen, Shujuan; Tao, Rong; Bai, Ou; Zou, Liqun; Li, Lanfang; Qiu, Lihua; Qian, Zhengzi; Zhou, Shiyong; Song, Yuqin; Zhang, Qingyuan; Wang, Xianhuo; Zhang, Huilai |
| 2016 | Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells | Zhang, Wen; Bao, Li; Yang, Shaoxing; Qian, Zhaoyang; Dong, Mei; Yin, Liyuan; Zhao, Qian; Ge, Keli; Deng, Zhenling; Zhang, Jing; Qi, Fei; An, Zhongxue; Yu, Yuan; Wang, Qingbo; Wu, Renhua; Fan, Fan; Zhang, Lianfeng; Chen, Xiping; Na, Yingjian; Feng, Lin; Liu, Lingling; Zhu, Yujie; Qin, Tiancheng; Zhang, Shuren; Zhang, Youhui; Zhang, Xiuqing; Wang, Jian; Yi, Xin; Zou, Liqun; Xin, Hong-Wu; Ditzel, Henrik J.; Gao, Hongjun; Zhang, Kaitai; Liu, Binlei; Cheng, Shujun |
